98%
921
2 minutes
20
Safety event reporting forms a cornerstone of identifying and mitigating risks to patient and staff safety. However, variabilities in reporting and limited resources to analyze and classify event reports delay healthcare organizations' ability to rapidly identify safety event trends and to improve workplace safety. We demonstrated how large language models can classify safety event report narratives as workplace violence (F1: 0.80 for physical violence; F1: 0.94 for verbal abuse) and communication failures (F1: 0.94) as a first step toward enabling automated labeling of safety event reports and ultimately improving workplace safety.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150719 | PMC |
Eye (Lond)
September 2025
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada.
Background: Blepharitis, meibomian gland dysfunction (MGD), and chalazia are common disorders impacting quality of life. This population-based, pharmacovigilance study aims to identify systemic drugs disproportionately linked to these disorders.
Methods: Data from the Food and Drug Administration Adverse Event Reporting System (FAERS) were analysed (Q4 2003 to Q2 2024).
Eur J Clin Pharmacol
September 2025
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.
Background: Heparin-induced thrombocytopenia (HIT) is a severe primary hypercoagulable disorder, particularly concerning in hemodialysis (HD) patients frequently exposed to heparin. Fondaparinux has emerged as a potential alternative anticoagulant, though supporting evidence is limited. This systematic review aimed to evaluate the safety and efficacy of fondaparinux in HD patients with HIT.
View Article and Find Full Text PDFArch Cardiovasc Dis
September 2025
Department of Orthopaedics, Shaoxing Keqiao Women & Children's Hospital, Shaoxing 312030, Zhejiang, China. Electronic address:
Background: Sacubitril/valsartan is a widely used cardiovascular agent characterized by its dual inhibition of the renin-angiotensin-aldosterone system and neprilysin. However, existing evidence on the safety of sacubitril/valsartan is primarily limited to clinical studies; this results in an inability to provide a timely update on associated adverse events.
Aim: To mine and systematically describe adverse events related to sacubitril/valsartan from September 2015 to June 2024 using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Cardiovasc Revasc Med
September 2025
Division of Vascular Surgery, Cardiovascular Center, Tufts Medical Center, Boston, MA, USA; Tufts University School of Medicine, Boston, MA, USA. Electronic address:
Background: protamine sulfate is used to reduce bleeding risk after Carotid Artery Stenting (CAS), but its efficacy in personalized patient settings remains underexplored. This study aims to identify factors associated with greater benefits from protamine sulfate following CAS.
Methods: A retrospective review of Vascular Quality Initiative (VQI) data (2016-2022) identified patients undergoing CAS, divided into Transfemoral CAS (TF-CAS) and Transcarotid artery revascularization (TCAR) groups.
Risk Anal
September 2025
School of Public Policy and Administration, Chongqing University, Chongqing, China.
Climate change is causing a significant increase in the number of compound extreme events that pose significantly greater threats to public safety. Chongqing is a megacity in southwestern China that took the brunt of temporally compounding events (TCEs) in the summer of 2022. We developed an approach based on the Intergovernmental Panel on Climate Change (IPCC) risk framework to assess the public health risks posed by TCEs.
View Article and Find Full Text PDF